Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Haukås · SciRah

Researcher profile · Semantic Scholar

E. Haukås

Share profile

E. Haukås — researcher profile on SciRah

h-index: 13
Works: 51
Citations: 1,043

Most-cited papers

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
A. Waage, P. Gimsing, P. Fayers, N. Abildgaard +21 more
2010Blood241 citations Open access
Semantic Scholar
Cold agglutinin disease revisited: A multinational, observational study of 232 patients.
S. Berentsen, W. Barcellini, S. D'Sa, U. Randen +19 more
2020Blood156 citations Open access
Semantic Scholar
Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.
S. Berentsen, U. Randen, M. Oksman, H. Birgens +9 more
2017Blood143 citations
Semantic Scholar
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
U. Mellqvist, P. Gimsing, O. Hjertner, S. Lenhoff +21 more
2013Blood143 citations Open access
Semantic Scholar
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
S. Zweegman, B. van der Holt, U. Mellqvist, M. Salomo +24 more
2016Blood119 citations Open access
Semantic Scholar
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
U. Mellqvist, J. Westin, P. Gimsing, O. Hjertner +22 more
200928 citations
Semantic Scholar
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
S. Zweegman, C. Stege, E. Haukås, F. Schjesvold +22 more
2018Haematologica27 citations Open access
Semantic Scholar
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study
L. K. Nielsen, C. Stege, Birgit I. Lissenberg-Witte, B. van der Holt +26 more
2019Haematologica25 citations Open access
Semantic Scholar
Improved progression free survival with bortezomib consolidation after high dose melphalan: results of a randomised phase III trial
U. H. Mellquist, P. Gimsing, O. Hjertner, S. Lenhoff +25 more
201123 citations
Semantic Scholar
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Thomas Lund, M. Gundesen, Annette Juul Vangsted, C. Helleberg +10 more
2024Blood Cancer Journal16 citations Open access
Semantic Scholar
Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma
Kristin R. Aass, Tonje Marie Vikene Nedal, S. S. Tryggestad, E. Haukås +4 more
2022Scientific Reports16 citations Open access
Semantic Scholar
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.
F. Askeland, E. Haukås, T. Slørdahl, A. Klostergaard +6 more
2025The Lancet Haematology15 citations
Semantic Scholar
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
Sonja Zweegman, C. Stege, E. Haukås, F. Schjesvold +22 more
2020Haematologica15 citations Open access
Semantic Scholar
Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study
F. Askeland, Anne-Marie Rasmussen, A. Lysén, E. Haukås +14 more
2023Blood14 citations Open access
Semantic Scholar
Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival
Kristin Roseth Aass, Tonje Marie Vikene Nedal, Siri Anshushaug Bouma, S. S. Tryggestad +5 more
2022British Journal of Cancer8 citations Open access
Semantic Scholar
A prospective study of Skeletal survey versus Low‐dose whole‐body CT for Osteolytic lesions in Multiple Myeloma
M. Gundesen, J. Asmussen, E. Haukås, M. Schubert +3 more
2022European Journal of Haematology7 citations Open access
Semantic Scholar
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
A. Schmitz, R. Brøndum, H. Johnsen, U. Mellqvist +23 more
2022BMC Cancer7 citations Open access
Semantic Scholar
Potential value of pre-planned imaging of bone disease in multiple myeloma
M. Gundesen, J. Asmussen, F. Schjesvold, A. Vangsted +10 more
2023Blood Cancer Journal6 citations Open access
Semantic Scholar
Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group
C. Stege, P. Sonneveld, T. Plesner, M. Stevens-Kroef +27 more
20176 citations
Semantic Scholar
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
A. Partanen, A. Waage, Valdas Pečeliūnas, F. Schjesvold +25 more
2024Cancers5 citations Open access
Semantic Scholar
24th Annual Conference of the International Society for Quality of Life Research
L. Nielsen, C. Stege, B. Witte, B. van der Holt +12 more
2017Quality of Life Research4 citations
Semantic Scholar
[Survival in adults with acute myelogenous leukemia].
J. Tangen, Y. Fløisand, Jenny Foss-Abrahamsen, E. Haukås +2 more
2008Tidsskrift for Den Norske Laegeforening4 citations
Semantic Scholar
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
K. Groen, F. Schjesvold, B. van der Holt, M. Levin +21 more
2023HemaSphere3 citations Open access
Semantic Scholar
Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study
F. Askeland, E. Haukås, T. Slørdahl, D. Schjøll +3 more
2022Blood3 citations Open access
Semantic Scholar
P-349 Multiple Myeloma Patients Who Are in VGPR or Better Benefits From Continued Treatment With Zoledronic Acid Beyond Two Years
Thomas Lund, M. Gundesen, A. Vangsted, C. Helleberg +10 more
2024Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
M. Gundesen, F. Schjesvold, A. Vangsted, C. Helleberg +10 more
2023HemaSphere2 citations Open access
Semantic Scholar
[Survival in adults with acute lymphoblastic leukaemia].
J. Tangen, Y. Fløisand, E. Haukås, I. Naess +3 more
2010Tidsskrift for Den Norske Laegeforening2 citations Open access
Semantic Scholar
A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group
Diana Loigom, T. Slørdahl, A. Lysén, Agoston Gyula Szabo +18 more
2024Blood1 citations
Semantic Scholar
Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study
F. Askeland, E. Haukås, T. Slørdahl, A. Klostergaard +5 more
2023Blood1 citations
Semantic Scholar
OA-10 Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple myeloma
M. Gundesen, F. Schjesvold, A. Vangsted, C. Helleberg +9 more
2023Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
Quality of life with melphalan/prednisone plus either thalidomide (MPT-T) or lenalidomide (MPR-R) in non-transplant eligible newly diagnosed multiple myeloma: results of the HOVON87/NMSG18 study
C. Stege, L. K. Nielsen, B. Witte, B. van der Holt +29 more
20171 citations
Semantic Scholar
PA-272 Ixazomib, Lenalidomide, Dexamethasone Treatment With Cytogenetic Risk-Based Maintenance in Transplant-Eligible Multiple Myeloma Patients: The Expanded Results of a Phase 2 Study
R. Silvennoinen, A. Partanen, A. Waage, Valdas Pečeliūnas +21 more
2026Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers
M. Gundesen, A. Vangsted, C. Helleberg, E. Haukås +14 more
2026British Journal of Haematology0 citations Open access
Semantic Scholar
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
F. Askeland, Vilhelm Hauge Bugge, Anne-Marie Rasmussen, A. Lysén +16 more
2025Blood Cancer Journal0 citations Open access
Semantic Scholar
A Phase 2 Study Measuring MRD Negativity after Talquetamab and Teclistamab Consolidation in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC)
Diana Loigom, T. S. Slørdahl, J. N. Nørgaard, E. Haukås +17 more
2025Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe), report of primary endpoint, nordic myeloma study group 29/21
Ida Bruun Kristensen, H. Norseth, Diana Loigom, H. Gregersen +7 more
2025Blood0 citations
Semantic Scholar
Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study
F. Askeland, E. Haukås, T. Slørdahl, A. Klostergaard +5 more
2024Blood0 citations
Semantic Scholar
Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21
Ida Bruun Kristensen, H. Norseth, Diana Loigom, H. Gregersen +6 more
2024Blood0 citations
Semantic Scholar
A young man with acute abdomen and anaemia.
M. Roalsø, Lars Karlsen, P. Buchmann, E. Haukås +1 more
2023Tidsskrift for Den Norske Laegeforening0 citations Open access
Semantic Scholar
P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
R. Silvennoinen, A. Partanen, A. Waage, Valdas Pečeliūnas +24 more
2023HemaSphere0 citations Open access
Semantic Scholar
P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
Frida Bugge Askeland, E. Haukås, T. Slørdahl, A. Klostergaard +5 more
2023HemaSphere0 citations Open access
Semantic Scholar
P-082 Will survival improve by treating multiple myeloma patients at MRD relapse? The REMNANT study
Anne-Marie Rasmussen, F. Askeland, A. Lysén, E. Haukås +13 more
2023Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
A. Schmitz, R. Brøndum, H. Johnsen, U. Mellqvist +23 more
2022BMC Cancer0 citations Open access
Semantic Scholar
P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients
R. Silvennoinen, A. Waage, Valdas Pečeliūnas, F. Schjesvold +20 more
2022Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
F. Askeland, Alice Rasmussen, A. Lysén, E. Haukås +12 more
2022HemaSphere0 citations Open access
Semantic Scholar
P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
K. Groen, M. Seefat, B. van der Holt, F. Schjesvold +22 more
2022HemaSphere0 citations Open access
Semantic Scholar
P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
F. Askeland, E. Haukås, T. Slørdahl, D. Schjøll +3 more
2022HemaSphere0 citations Open access
Semantic Scholar
P-030: Regular monitoring with whole body low-dose CT for osteolysis in multiple myeloma reveals more cases of progressive bone disease than imaging performed by clinical indication
M. Gundesen, J. Asmussen, F. Schjesvold, A. Vangsted +10 more
2022Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
P-146: A prospective study of conventional skeletal survey versus Whole-body CT for osteolytic lesions in Multiple Myeloma
M. Gundesen, J. Asmussen, E. Haukås, M. Schubert +3 more
2021Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Lymphomatoid granulomatosis: a mimicker of systemic inflammatory rheumatological disease
J. Vikse, K. Bryne, E. Haukås, F. Leh +2 more
2020Scandinavian Journal of Rheumatology0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Waage×20
Invite
A. Waage — researcher profile on SciRah
F. Schjesvold×19
Invite
F. Schjesvold — researcher profile on SciRah
T. Slørdahl×19
Invite
T. Slørdahl — researcher profile on SciRah
N. Abildgaard×17
Invite
N. Abildgaard — researcher profile on SciRah

×16

Invite

D. Szatkowski — researcher profile on SciRah

F. Schjesvold×14

Invite

F. Schjesvold — researcher profile on SciRah

U. Mellqvist×13

Invite

U. Mellqvist — researcher profile on SciRah

Invite

H. Nahi — researcher profile on SciRah

Invite

M. Hansson — researcher profile on SciRah

Invite

A. Lysén — researcher profile on SciRah

Invite

P. Gimsing — researcher profile on SciRah

B. van der Holt×10

Invite

B. van der Holt — researcher profile on SciRah